Pharmaceutical Body EFPIA and Lithuanian Ministry of Health Galvanise Future Innovation and Improvements to Public Health with Landmark Joint Working Agreement
he Lithuanian Ministry of Health and EFPIA, the European Federation of Pharmaceutical Industries and Associations announced a significant new Joint Working Agreement that paves the way for protecting future health and growth in Lithuanian.
The Lithuanian Ministry of Health and EFPIA, the European Federation of Pharmaceutical Industries and Associations (their member in Lithuania - the Association of Innovative Pharmaceutical Industry (IFPA), have today announced a significant new Joint Working Agreement that paves the way for protecting future health and growth in Lithuanian.
The agreement is a concrete step towards delivering the vision of health and sustainable growth set out in the
Lithuanian Minister of Health Vytenis Povilas Andriukaitis stated: “We are creating a sustainable health care system that is prone to demographic and economic challenges, that promptly responds to current health threats, that incorporates newest technologies and best medical practices. The Ministry of Health and EFPIA working together means new treatment options for the patients, greater transparency for the healthcare industry and meaningful cooperation with innovative businesses.”
Through partnering on a holistic life sciences strategy, EFPIA and the Lithuanian Ministry of Health intend to make Lithuania a more attractive location for life sciences investment, and to support a healthy population through the creation of more effective, efficient and sustainable health systems.
EFPIA Director General Richard Bergström stated: “Our industry has entered into a number of agreements with European governments, but the Lithuanian agreement has achieved a new progressive, gold standard in collaboration for better health outcomes. It signifies a new dawn in our industry’s partnerships, as it delivers a much more comprehensive solution to meeting the health and economic needs of citizens. I urge other nations to learn from the Lithuanian approach.”
The agreement was born from a recognised need to protect patients, public health and medical progress in Lithuania.
The Joint Working Agreement,
- Increase investment in health promotion and disease prevention;
- Ensure universal access to high-quality, people-centred health services;
- Ensure that health system reforms – including workforce planning – are evidence-based and focus on cost-effectiveness, sustainability and good governance;
- Establish a three-year cycle for management of funds allocated under for reimbursement of medicines (the Reimbursement Budget). The growth of the Reimbursement Budget shall reflect and be proportionate to both GDP growth and increase in overall public health care spending.
Such collaborative efforts are integral to EFPIA’s recently launched strategy,
“Health and Growth: Working together for a healthy Europe”
, which advocates for an integrated life sciences sector for the EU. Cross-sectoral approaches to health policy will be essential to realising this vision, and EFPIA hopes that the agreement signed with the Lithuanian Ministry of Health will serve as a positive example of how we can expand the conversation on how to foster excellence, equity and sustainability in European healthcare systems.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025